Opko Health Inc. (OPK) Given “Hold” Rating at Oppenheimer Holdings Inc.
Opko Health Inc. (NYSE:OPK)‘s stock had its “hold” rating restated by stock analysts at Oppenheimer Holdings Inc. in a research report issued on Monday.
Several other research analysts have also recently weighed in on the stock. Jefferies Group reissued a “hold” rating and set a $10.00 price objective on shares of Opko Health in a report on Monday. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a report on Tuesday, August 9th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Standpoint Research boosted their price objective on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, June 21st. Finally, Deutsche Bank AG decreased their price objective on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a report on Thursday, June 16th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $13.20.
Opko Health (NYSE:OPK) traded down 3.5487% during mid-day trading on Monday, reaching $9.5969. 1,591,803 shares of the company’s stock traded hands. The company has a market cap of $5.28 billion and a P/E ratio of 40.1544. The stock has a 50 day moving average of $10.06 and a 200 day moving average of $10.09. Opko Health has a 12-month low of $7.12 and a 12-month high of $11.85.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/opko-health-inc-opk-given-hold-rating-at-oppenheimer-holdings-inc.html
Opko Health (NYSE:OPK) last issued its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analysts’ expectations of $324.11 million. During the same period last year, the firm posted ($0.09) earnings per share. The firm’s quarterly revenue was up 742.2% on a year-over-year basis. On average, equities research analysts predict that Opko Health will post ($0.05) earnings per share for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 15,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 13th. The stock was bought at an average cost of $9.65 per share, for a total transaction of $152,470.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $29,615,377.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Several institutional investors have recently bought and sold shares of the company. Bridger Management LLC purchased a new position in Opko Health during the first quarter worth $13,863,000. Amici Capital LLC purchased a new position in Opko Health during the first quarter worth $842,000. Schonfeld Strategic Advisors LLC purchased a new position in Opko Health during the first quarter worth $141,000. LGL Partners LLC purchased a new position in Opko Health during the first quarter worth $556,000. Finally, Geode Capital Management LLC raised its position in Opko Health by 6.6% in the first quarter. Geode Capital Management LLC now owns 1,923,455 shares of the company’s stock worth $19,984,000 after buying an additional 118,512 shares during the last quarter.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.